Clinical Trial Update: Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating durvalumab with chemotherapy and SBRT for oligometastatic non-small cell lung cancer. The status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN